ConductScience.org, home

Paper40488994

Novel therapeutic strategies targeting infections caused by P. aeruginosa biofilm.

Lekhwar R and 4 others. Mol Biol Rep, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Novel therapeutic strategies targeting infections caused by P. aeruginosa biofilm. Papers, record 40488994. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40488994

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Novel therapeutic strategies targeting infections caused by P. aeruginosa biofilm.
PubMed
Journal
Mol Biol Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-11-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lekhwar RRajeshwari
2Kumar SSunilhttps://orcid.org/0000-0002-0689-2244
3Tripathi MMahima
4Gangola SSaurabh
5Sharma AKAnil Kumar

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BiofilmsMajor topic
Pseudomonas aeruginosaMajor topic
Pseudomonas InfectionsMajor topic
Humans
Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Phage Therapy
Antimicrobial Peptides
Immunotherapy

Source PubMed

Download CSV of topics

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137771093Structural analysis of novel drug targets for mitigation of Pseudomonas aeruginosa biofilms.FEMS Microbiol Rev2023https://conductscience.org/library/papers/37771093PubMed
238501823Antibacterial peptide Reg4 ameliorates Pseudomonas aeruginosa-induced pulmonary inflammation and fibrosis.Microbiol Spectr2024https://conductscience.org/library/papers/38501823PubMed
338886583Bacteriophage protein Dap1 regulates evasion of antiphage immunity and Pseudomonas aeruginosa virulence impacting phage therapy in mice.Nat Microbiol2024https://conductscience.org/library/papers/38886583PubMed
438428090Bacterial profiles detected in ventilator-associated pneumonia in Japan: A systematic review.Respir Investig2024https://conductscience.org/library/papers/38428090PubMed
538653744Phage-antibiotic combinations to control Pseudomonas aeruginosa-Candida two-species biofilms.Sci Rep2024https://conductscience.org/library/papers/38653744PubMed
638594311A folate inhibitor exploits metabolic differences in Pseudomonas aeruginosa for narrow-spectrum targeting.Nat Microbiol2024https://conductscience.org/library/papers/38594311PubMed
738214500Inhibition of polymorphic MexXY-OprM efflux system in Pseudomonas aeruginosa clinical isolates by Berberine derivatives.ChemMedChem2024https://conductscience.org/library/papers/38214500PubMed
837795577Is Short-Course Antibiotic Therapy Suitable for Pseudomonas aeruginosa Bloodstream Infections in Onco-hematology Patients With Febrile Neutropenia? Results of a Multi-institutional Analysis.Clin Infect Dis2024https://conductscience.org/library/papers/37795577PubMed
936130230Less Is More? Antibiotic Treatment Duration in Pseudomonas aeruginosa Ventilator-Associated Pneumonia.Clin Infect Dis2023https://conductscience.org/library/papers/36130230PubMed
1039224938Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study.J Antimicrob Chemother2024https://conductscience.org/library/papers/39224938PubMed
1138745145Evaluation of fortimicin antibiotic combinations against MDR Pseudomonas aeruginosa and resistome analysis of a whole genome sequenced pan-drug resistant isolate.BMC Microbiol2024https://conductscience.org/library/papers/38745145PubMed
1239383099Comment on: Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study.J Antimicrob Chemother2024https://conductscience.org/library/papers/39383099PubMed
1338097907Biofilm formation: mechanistic insights and therapeutic targets.Mol Biomed2023https://conductscience.org/library/papers/38097907PubMed
1439431861Urinary tract infections and catheter-associated urinary tract infections caused by Pseudomonas aeruginosa.Microbiol Mol Biol Rev2024https://conductscience.org/library/papers/39431861PubMed
1537627724The Art of War with Pseudomonas aeruginosa: Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy.Antibiotics (Basel)2023https://conductscience.org/library/papers/37627724PubMed
1633147726Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice.Vaccines (Basel)2020https://conductscience.org/library/papers/33147726PubMed
1735967851Multidrug-resistant Pseudomonas aeruginosa is predisposed to lasR mutation through up-regulated activity of efflux pumps in non-cystic fibrosis bronchiectasis patients.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/35967851PubMed
1835442072Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.Microbiol Spectr2022https://conductscience.org/library/papers/35442072PubMed
1940272253Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce Pseudomonas aeruginosa burden in mice.Elife2025https://conductscience.org/library/papers/40272253PubMed
2032931584The Genomic Basis of Rapid Adaptation to Antibiotic Combination Therapy in Pseudomonas aeruginosa.Mol Biol Evol2021https://conductscience.org/library/papers/32931584PubMed

See all 61 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42076093Functional Peptides: Comparing Synthetic and Sequence-Engineered Antibiofilm Pharmaceutics.Pharmaceutics2026https://conductscience.org/library/papers/42076093PubMed
41220486Eco-friendly nanoparticles from Fusarium solani suppress biofilms and quorum sensing in Pseudomonas aeruginosa.Nanoscale Adv2026https://conductscience.org/library/papers/41220486PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40488994

GET https://conductscience.org/api/papers/v1/40488994/references?page=2